Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

T-B-NK+ SCID: Pathogenesis and genetics

Morton J Cowan, MD
Section Editor
Jennifer M Puck, MD
Deputy Editor
Elizabeth TePas, MD, MS


An extreme form of severe combined immunodeficiency disease (SCID) is the T cell-negative (T-), B cell-negative (B-), natural killer cell-positive (NK+) SCID phenotype, which accounts for approximately one-quarter of all cases of SCID. Unless identified by newborn screening, children with T-B-NK+ SCID present early in life with serious to life-threatening infections, failure to thrive, low to absent T and B cell numbers and function, and normal numbers and function of NK cells.

This form of SCID can result from autosomal recessive defects in any of several genes that encode proteins involved in antigen receptor gene V(D)J recombination. The recombination process randomly combines variable, diversity, and joining gene segments that encode T cell receptor (TCR) and immunoglobulin genes in T and B cells, respectively. Some of the proteins encoded by these genes are also involved in DNA repair in all cells of the body. Defects in these genes are associated with extra-immune phenotypes, including growth and developmental abnormalities and heightened sensitivity to ionizing radiation and chemotherapy.

The pathogenesis and genetics of T-B-NK+ SCID diseases are reviewed here. The clinical manifestations, diagnosis, and treatment of T-B-NK+ SCID are discussed in greater detail separately. An overview of SCID and the different forms of SCID are also presented separately. (See "Severe combined immunodeficiency (SCID): An overview" and "Severe combined immunodeficiency (SCID): Specific defects" and "T-B-NK+ SCID: Clinical manifestations, diagnosis, and treatment".)


All the known causes for T-B-NK+ SCID (table 1) involve defects in V(D)J recombination of antigen receptor genes in T and B cells [1-10]. V(D)J recombination is the process by which the immune system generates a vastly diverse repertoire of T and B cell receptors capable of recognizing a huge number of potential pathogens [11,12]. These receptors contain variable domains that represent the recognition portion of each specific receptor molecule. The biology underlying V(D)J recombination is reviewed here. These processes are also discussed in detail separately. (See "T cell receptor genetics" and "Immunoglobulin genetics".)

Recombination mechanisms — The coding regions of DNA for the variable domains of T and B cell receptor genes are assembled during the early stages of T and B cell maturation. This process involves site-specific DNA rearrangement to select one of each of a large tandem array of alternate segments of DNA called variable (V), diversity (D), and joining (J). For every specific antigen receptor, there is a V and J gene segment and sometimes a D gene segment that are randomly selected and ligated together via a process called V(D)J recombination. Highly conserved sequences of DNA, termed recombination signal sequences (RSSs), flank all of the V, D, and J coding regions and facilitate this process.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Aug 18, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Abe T, Tsuge I, Kamachi Y, et al. Evidence for defects in V(D)J rearrangements in patients with severe combined immunodeficiency. J Immunol 1994; 152:5504.
  2. Schwarz K, Gauss GH, Ludwig L, et al. RAG mutations in human B cell-negative SCID. Science 1996; 274:97.
  3. Moshous D, Callebaut I, de Chasseval R, et al. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell 2001; 105:177.
  4. Blunt T, Gell D, Fox M, et al. Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse. Proc Natl Acad Sci U S A 1996; 93:10285.
  5. Wiler R, Leber R, Moore BB, et al. Equine severe combined immunodeficiency: a defect in V(D)J recombination and DNA-dependent protein kinase activity. Proc Natl Acad Sci U S A 1995; 92:11485.
  6. Meek K, Kienker L, Dallas C, et al. SCID in Jack Russell terriers: a new animal model of DNA-PKcs deficiency. J Immunol 2001; 167:2142.
  7. de Villartay JP. V(D)J recombination and DNA repair: lessons from human immune deficiencies and other animal models. Curr Opin Allergy Clin Immunol 2002; 2:473.
  8. van der Burg M, Ijspeert H, Verkaik NS, et al. A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis activation and nonhomologous end-joining. J Clin Invest 2009; 119:91.
  9. Enders A, Fisch P, Schwarz K, et al. A severe form of human combined immunodeficiency due to mutations in DNA ligase IV. J Immunol 2006; 176:5060.
  10. Woodbine L, Neal JA, Sasi NK, et al. PRKDC mutations in a SCID patient with profound neurological abnormalities. J Clin Invest 2013; 123:2969.
  11. Fugmann SD, Lee AI, Shockett PE, et al. The RAG proteins and V(D)J recombination: complexes, ends, and transposition. Annu Rev Immunol 2000; 18:495.
  12. Grawunder U, Harfst E. How to make ends meet in V(D)J recombination. Curr Opin Immunol 2001; 13:186.
  13. Shinkai Y, Rathbun G, Lam KP, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992; 68:855.
  14. Mombaerts P, Iacomini J, Johnson RS, et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992; 68:869.
  15. Lieber MR. The biochemistry and biological significance of nonhomologous DNA end joining: an essential repair process in multicellular eukaryotes. Genes Cells 1999; 4:77.
  16. Deriano L, Roth DB. Modernizing the nonhomologous end-joining repertoire: alternative and classical NHEJ share the stage. Annu Rev Genet 2013; 47:433.
  17. Gu Y, Sekiguchi J, Gao Y, et al. Defective embryonic neurogenesis in Ku-deficient but not DNA-dependent protein kinase catalytic subunit-deficient mice. Proc Natl Acad Sci U S A 2000; 97:2668.
  18. Gao Y, Sun Y, Frank KM, et al. A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis. Cell 1998; 95:891.
  19. Bosma MJ, Carroll AM. The SCID mouse mutant: definition, characterization, and potential uses. Annu Rev Immunol 1991; 9:323.
  20. Barnes DE, Stamp G, Rosewell I, et al. Targeted disruption of the gene encoding DNA ligase IV leads to lethality in embryonic mice. Curr Biol 1998; 8:1395.
  21. Varon R, Vissinga C, Platzer M, et al. Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 1998; 93:467.
  22. Zhu C, Bogue MA, Lim DS, et al. Ku86-deficient mice exhibit severe combined immunodeficiency and defective processing of V(D)J recombination intermediates. Cell 1996; 86:379.
  23. Gu Y, Seidl KJ, Rathbun GA, et al. Growth retardation and leaky SCID phenotype of Ku70-deficient mice. Immunity 1997; 7:653.
  24. Critchlow SE, Bowater RP, Jackson SP. Mammalian DNA double-strand break repair protein XRCC4 interacts with DNA ligase IV. Curr Biol 1997; 7:588.
  25. Mahaney BL, Meek K, Lees-Miller SP. Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem J 2009; 417:639.
  26. Frank KM, Sharpless NE, Gao Y, et al. DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway. Mol Cell 2000; 5:993.
  27. Li Y, Chirgadze DY, Bolanos-Garcia VM, et al. Crystal structure of human XLF/Cernunnos reveals unexpected differences from XRCC4 with implications for NHEJ. EMBO J 2008; 27:290.
  28. Riballo E, Woodbine L, Stiff T, et al. XLF-Cernunnos promotes DNA ligase IV-XRCC4 re-adenylation following ligation. Nucleic Acids Res 2009; 37:482.
  29. Akopiants K, Zhou RZ, Mohapatra S, et al. Requirement for XLF/Cernunnos in alignment-based gap filling by DNA polymerases lambda and mu for nonhomologous end joining in human whole-cell extracts. Nucleic Acids Res 2009; 37:4055.
  30. Li L, Moshous D, Zhou Y, et al. A founder mutation in Artemis, an SNM1-like protein, causes SCID in Athabascan-speaking Native Americans. J Immunol 2002; 168:6323.
  31. Zhang X, Succi J, Feng Z, et al. Artemis is a phosphorylation target of ATM and ATR and is involved in the G2/M DNA damage checkpoint response. Mol Cell Biol 2004; 24:9207.
  32. Moshous D, Li L, Chasseval R, et al. A new gene involved in DNA double-strand break repair and V(D)J recombination is located on human chromosome 10p. Hum Mol Genet 2000; 9:583.
  33. Ma Y, Pannicke U, Schwarz K, Lieber MR. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 2002; 108:781.
  34. Noordzij JG, Verkaik NS, van der Burg M, et al. Radiosensitive SCID patients with Artemis gene mutations show a complete B-cell differentiation arrest at the pre-B-cell receptor checkpoint in bone marrow. Blood 2003; 101:1446.
  35. Li L, Salido E, Zhou Y, et al. Targeted disruption of the Artemis murine counterpart results in SCID and defective V(D)J recombination that is partially corrected with bone marrow transplantation. J Immunol 2005; 174:2420.
  36. Saidi A, Li T, Weih F, et al. Dual functions of Nbs1 in the repair of DNA breaks and proliferation ensure proper V(D)J recombination and T-cell development. Mol Cell Biol 2010; 30:5572.
  37. Villa A, Sobacchi C, Notarangelo LD, et al. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood 2001; 97:81.
  38. Niehues T, Perez-Becker R, Schuetz C. More than just SCID--the phenotypic range of combined immunodeficiencies associated with mutations in the recombinase activating genes (RAG) 1 and 2. Clin Immunol 2010; 135:183.
  39. Asai E, Wada T, Sakakibara Y, et al. Analysis of mutations and recombination activity in RAG-deficient patients. Clin Immunol 2011; 138:172.
  40. Villa A, Notarangelo LD, Roifman CM. Omenn syndrome: inflammation in leaky severe combined immunodeficiency. J Allergy Clin Immunol 2008; 122:1082.
  41. Grunebaum E, Bates A, Roifman CM. Omenn syndrome is associated with mutations in DNA ligase IV. J Allergy Clin Immunol 2008; 122:1219.
  42. Santagata S, Villa A, Sobacchi C, et al. The genetic and biochemical basis of Omenn syndrome. Immunol Rev 2000; 178:64.
  43. Lee YN, Frugoni F, Dobbs K, et al. A systematic analysis of recombination activity and genotype-phenotype correlation in human recombination-activating gene 1 deficiency. J Allergy Clin Immunol 2014; 133:1099.
  44. Walter JE, Rosen LB, Csomos K, et al. Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. J Clin Invest 2015; 125:4135.
  45. Buchbinder D, Baker R, Lee YN, et al. Identification of patients with RAG mutations previously diagnosed with common variable immunodeficiency disorders. J Clin Immunol 2015; 35:119.
  46. Walter JE, Rucci F, Patrizi L, et al. Expansion of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiency. J Exp Med 2010; 207:1541.
  47. Appleton AL, Curtis A, Wilkes J, Cant AJ. Differentiation of materno-fetal GVHD from Omenn's syndrome in pre-BMT patients with severe combined immunodeficiency. Bone Marrow Transplant 1994; 14:157.
  48. Shearer WT, Dunn E, Notarangelo LD, et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol 2014; 133:1092.
  49. Corneo B, Moshous D, Güngör T, et al. Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. Blood 2001; 97:2772.
  50. Nahas SA, Gatti RA. DNA double strand break repair defects, primary immunodeficiency disorders, and 'radiosensitivity'. Curr Opin Allergy Clin Immunol 2009; 9:510.
  51. Nicolas N, Moshous D, Cavazzana-Calvo M, et al. A human severe combined immunodeficiency (SCID) condition with increased sensitivity to ionizing radiations and impaired V(D)J rearrangements defines a new DNA recombination/repair deficiency. J Exp Med 1998; 188:627.
  52. Cowan MJ, University of California, 2014, personal communication.
  53. Woodbine L, Gennery AR, Jeggo PA. The clinical impact of deficiency in DNA non-homologous end-joining. DNA Repair (Amst) 2014; 16:84.
  54. Cowan MJ, Gennery AR. Radiation-sensitive severe combined immunodeficiency: The arguments for and against conditioning before hematopoietic cell transplantation--what to do? J Allergy Clin Immunol 2015; 136:1178.
  55. Murphy S, Hayward A, Troup G, et al. Gene enrichment in an American Indian population: an excess of severe combined immunodeficiency disease. Lancet 1980; 2:502.
  56. Krauss ME. Native languages of the Americas, Sebeok TA (Ed), Plenum Press, New York 1979. p.150.
  57. Kehoe AB. North American Indians: A comprehensive account, Prentice-Hall, 1981. p.449.
  58. Jones JF, Ritenbaugh CK, Spence MA, Hayward A. Severe combined immunodeficiency among the Navajo. I. Characterization of phenotypes, epidemiology, and population genetics. Hum Biol 1991; 63:669.
  59. Puck JM, University of California, 2014, personal communication.
  60. Renfrew C. World linguistic diversity. Sci Am 1994; 270:116.
  61. Li L, Drayna D, Hu D, et al. The gene for severe combined immunodeficiency disease in Athabascan-speaking Native Americans is located on chromosome 10p. Am J Hum Genet 1998; 62:136.
  62. Xiao Z, Yannone SM, Dunn E, Cowan MJ. A novel missense RAG-1 mutation results in T-B-NK+ SCID in Athabascan-speaking Dine Indians from the Canadian Northwest Territories. Eur J Hum Genet 2009; 17:205.
  63. O'Marcaigh AS, Puck JM, Pepper AE, et al. Maternal mosaicism for a novel interleukin-2 receptor gamma-chain mutation causing X-linked severe combined immunodeficiency in a Navajo kindred. J Clin Immunol 1997; 17:29.
  64. van der Burg M, van Dongen JJ, van Gent DC. DNA-PKcs deficiency in human: long predicted, finally found. Curr Opin Allergy Clin Immunol 2009; 9:503.
  65. Cowan MJ, Puck JM, University of California, 2014, personal communication.